- Home
- IMVT vs CLVT Comparison
IMVT vs CLVT Comparison
Compare IMVT & CLVT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IMVT
- CLVT
- Stock Information
- Founded
- IMVT 2018
- CLVT 2016
- Country
- IMVT United States
- CLVT United Kingdom
- Employees
- IMVT N/A
- CLVT N/A
- Industry
- IMVT Biotechnology: Biological Products (No Diagnostic Substances)
- CLVT EDP Services
- Sector
- IMVT Health Care
- CLVT Technology
- Exchange
- IMVT Nasdaq
- CLVT Nasdaq
- Market Cap
- IMVT 2.7B
- CLVT 2.8B
- IPO Year
- IMVT N/A
- CLVT N/A
- Fundamental
- Price
- IMVT $15.53
- CLVT $4.17
- Analyst Decision
- IMVT Buy
- CLVT Hold
- Analyst Count
- IMVT 11
- CLVT 5
- Target Price
- IMVT $33.88
- CLVT $4.83
- AVG Volume (30 Days)
- IMVT 1.6M
- CLVT 3.8M
- Earning Date
- IMVT 11-06-2025
- CLVT 11-05-2025
- Dividend Yield
- IMVT N/A
- CLVT N/A
- EPS Growth
- IMVT N/A
- CLVT N/A
- EPS
- IMVT N/A
- CLVT N/A
- Revenue
- IMVT N/A
- CLVT $2,500,300,000.00
- Revenue This Year
- IMVT N/A
- CLVT N/A
- Revenue Next Year
- IMVT N/A
- CLVT N/A
- P/E Ratio
- IMVT N/A
- CLVT N/A
- Revenue Growth
- IMVT N/A
- CLVT N/A
- 52 Week Low
- IMVT $12.72
- CLVT $3.04
- 52 Week High
- IMVT $32.10
- CLVT $7.15
- Technical
- Relative Strength Index (RSI)
- IMVT 46.91
- CLVT 45.16
- Support Level
- IMVT $16.08
- CLVT $4.11
- Resistance Level
- IMVT $17.20
- CLVT $4.54
- Average True Range (ATR)
- IMVT 0.79
- CLVT 0.15
- MACD
- IMVT 0.09
- CLVT -0.02
- Stochastic Oscillator
- IMVT 36.81
- CLVT 13.95
About IMVT Immunovant Inc.
Immunovant Inc is a clinical-stage immunology company dedicated to enabling normal lives for people with autoimmune diseases. Its focus is on developing IMVT-1402, a potential inhibitor of the neonatal fragment crystallizable receptor (FcRn), to address autoimmune diseases driven by high levels of pathogenic immunoglobulin G (IgG) antibodies. FcRn is involved in preventing the degradation of IgG antibodies, and inhibition of FcRn has been shown to reduce levels of total IgG and pathogenic IgG antibodies. The company operates in a single operating segment, which includes all activities related to the research, development and manufacturing of its product candidates.
About CLVT Clarivate Plc
Clarivate is a data, information, and software workflow solutions company serving customers primarily in academia, government, law, life sciences, and healthcare. The company was formerly part of Thomson Reuters before being sold to private equity as an independent company in 2016. In 2019, Clarivate went public on the New York Stock Exchange. Around half of the company's revenue is generated in the Americas while Europe, Middle East, and Africa account for around a quarter.